INTRODUCTION
The Agency for Toxic Substances and Disease Reg istry (ATSDR) derives minimal risk levels (MRLs) to assist in evaluating risk of adverse health effects in individuals exposed to hazardous' substances. The guidance for development of MRLs has been discussed elsewhere (Chou et al., 1998) . Substance-specific MRLs are discussed in the corresponding toxicological pro files developed by the agency. ATSDR toxicological pro files characterize the toxicologic and adverse health effect information for specific chemicals, by route and duration of exposure, and by health-effect end point.
The classification of end points is a critical compo nent in the MRL derivation process. Adverse effects are effects that reduce the capacity of an organism or a component of an organism to function in a normal manner. The concept of adversity and its relationship to MRL derivation has been discussed elsewhere (ATSDR, 1995a; Chou et al., 1998; Pohl and Abadin, 1995) . ATSDR classifies the dose levels in relation to adverse health effects into three categories: no-ob served-adverse-effect-Ievel (NOAEL), lowest-observed adverse-effect-Ievel (LOAEL), and serious LOAEL (Chou et al., 1998) . By definition, LOAELs are dose levels at which observed health effects prevent an or gan or organ system from functioning in a normal manner over a lifetime, but will not necessarily lead to the inability of the whole organism to function nor mally. Serious LOAELs are dose levels at which the observed effects prevent the organism from engaging in normal activity over a lifetime. ATSDR does not derive MRLs from serious LOAELs. In addition, the ATSDR Minimal Risk Level Workgroup has adopted the classification of minimal LOAEL to take into ac count effect levels that reduce the capacity of an organ or organ system to function normally, but do not nec essarily lead to the inability of the organ, organ sys tem, or the whole organism to function normally. This paper presents a brief overview of the hemato logical system and examples of adverse conditions. Specific examples of minimal risk levels derived from hematological end points are presented.
The Hematologic System
The hematopoietic system includes tissues and or gans necessary for the generation, maturation, and destruction of blood cells, as well as the blood cells themselves. These tissues and organs include the mononuclear phagocyte system, spleen, lymph nodes, thymus, bone marrow, and liver.
Hematopoiesis is the term used to describe the pro duction of blood cells. Three types of formed elements are found in the blood: red blood cells (RBCs) or eryth rocytes, white blood cells (WBCs) or leukocytes, and platelets (thrombocytes). In healthy individuals, the destruction and production of cells are balanced, and the number of cells present in the blood at any specific time is fairly constant.
In the fetus, hematopoiesis takes place at various stages in the liver, spleen, thymus, bone marrow, and lymph nodes. Hematopoiesis begins as early as the 19th day after fertilization in the yolk sac ofthe human embryo with the production of primitive RBCs. When the fetal liver becomes the major site of blood cell production at approximately the 3rd month of develop ment, the yolk sac ceases its function in hematopoiesis. Hematopoiesis also begins at this time in the spleen, kidney, thymus, and lymph nodes. The lymph nodes serve as an important site oflymphopoiesis throughout life, whereas blood production in the liver, spleen, kid ney, and thymus discontinues or decreases as the bone marrow becomes active in hematopoiesis. The bone marrow becomes the primary site of hematopoiesis at about the 6th month of development and continues as the primary source of blood production after birth and throughout life.
The erythrocyte is one of the most specialized cells in the body. Erythropoiesis is generally an orderly pro cess through which the peripheral concentration of erythrocytes is maintained in a steady state. Mem brane integrity is essential for normal erythrocyte function and survival. Inherited or acquired membrane abnormalities can lead to severe anemia. Since the mature RBC does not contain a nucleus, mitochondria, and other subcellular organelles, its metabolism is lim ited. The binding, transport, and release of CO 2 and O 2 are passive processes and do not require energy; how ever, a number of energy-dependent metabolic pro cesses occur that are essential to the survival of the RBC. The most important metabolic pathways require glucose as a substrate. The function of erythrocytes is to transport oxygen from the lungs to the tissue and to remove carbon dioxide from the tissue to the lungs. The highly specialized protein contained in erythrocytes that is responsible for transport of these gasses is he moglobin.
Leukocyte formation, followiJ)g specific hormonal stimulation, is initiated in the bone marrow and re sults in various types of leukocytes: granulocytes (which include neutrophils, eosinophils, and ba sophils), monocytes, and lymphocytes. Upon matura tion, these cells may be released into the peripheral blood, or they may remain in the bone marrow storage pool until needed. The defensive function of leukocytes includes two separate but interrelated events: phago cytosis and the subsequent development of the immune response. Granulocytes and monocytes are responsible for phagocytosis, while monocytes and lymphocytes in teract to produce an effective immune response.
Platelets are also derived in the bone marrow and are involved in several aspects of hemostasis (blood coagulation). One of the major roles of the platelet appears to be that of passive surveillance of the blood ,vessel endothelial lining for gaps and breaks. In the event of an injury in which there is an actual break in the continuity of the lining of the vessels, the platelets react by forming an aggregate known as the primary hemostatic platelet plug and arrest bleeding. Another function ofthe platelet is the promotion of tissue repair following the injury. Hematological effects encompass effects to any of the components of the blood or blood forming units. Although part of the hematological sys tem, the thymus and spleen can be classified as immu nologic due to their contribution to immunity.
Blood cell counts and various hematological mea surements are typically used to evaluate hematotoxic ity. These include, among others, erythrocyte count, thrombocyte count, and hematocrit and hemoglobin content. Effects on cell morphology and assessments of functional impairment of any component (e.g., heme synthesis) including hematopoiesis itself would consti tute hematotoxicity. The following represents a list and brief description of some parameters and condi tions used to evaluate hematotoxicity.
Potential End Points for MRL Derivation
Anemia. Anemia is a hematological condition that can result from various disease states including chem ical exposure. Simply stated, anemia indicates a de creased amount of hemoglobin and, consequently, re duced oxygen-carrying capacity of the blood that may lead to hypoxia. If hypoxic conditions occur, important tissues (e.g., brain) may be affected due to oxygen deprivation. Diagnosis of anemia is partly made through the determination of red cell count, hemoglo bin, and hematocrit. Morphologically, anemia can be classified according to average size and hemoglobin content of the circulating red blood cells. Red blood cell indices used to determine this include mean corpuscu lar volume or MCV, mean corpuscular hemoglobin or MCH, and mean corpuscular hemoglobin concentra tion or MCHC. These indices are often helpful since certain causes of anemia produce a characteristic mor phology. Several classifications of anemia have been formulated. Although these classifications are impor tant for the purpose of diagnosis and treatment, it is also important to note that a number of factors can complicate laboratory interpretation. These include multiple mechanism involvement or preexisting com plicating factors such as iron deficiency. In addition, off-setting morphologic expression can occur. For ex ample, iron deficiency typically results in microcytic red cells; with folate deficiency, red blood cells are usually macrocytic. In a combined iron and folate de ficiency, one might observe normal MCV (McKenzie et al., 1988) .
There are three functional classifications of anemia: proliferative, maturation, and survival. Proliferative defects may be caused by inappropriate production of the hormone erythropoietin and are associated with malignancies, chronic renal disease, and certain endo crinopatbies. The kidneys produce 80-90% of the body's erythropoietin (the liver is responsible for eryth ropoietin production in the fetus), which is the princi pal factor that stimulates RBC production. During hypoxia, erythropoietin production is increased, stim ulating production of RBCs to alleviate the hypoxia. Chemically induced kidney damage can result in the interruption of the erythropoietic stimulating mecha nism. Alternatively, this mechanism can be operating correctly, but the bone marrow may not be responding to the stimulus because of chemical damage to the marrow. In both of these cases, anemic conditions re sult, but the underlying mechanism can be due to quite different compounds acting upon two different organ systems.
Maturation defects are those that are characterized by a disruption in the normal development of the RBC. The bone marrow usually recognizes the abnormal cells and destroys them before they reach the periph eral circulation. Reticulocyte levels in the circulating blood are, therefore, usually low. Cytoplasmic matura tion defects are caused by abnormal hemoglobin pro duction, and the defect is limited to the erythroid cell line (McKenzie et at., 1988) . Examples include thalas semia, hemoglobinopathies, lead intoxication, and por phyrias. Nuclear maturation defects affect all cell lines including erythrocytes.
Survival defects result from premature loss of eryth rocytes by hemorrhage or hemolysis. A compensatory increase in bone marrow proliferation is observed as increased circulating reticulocytes. Other indicators include increased serum bilirubin, hemosiderinuria, hemoglobinuria, and hemoglobinemia (McKenzie et al., 1988) .
Methemoglobinemia. Methemoglobinemia refers to an increase in the amount of normal (2% of total he moglobin) methemoglobin in the circulation. Methemo globin contains ferric rather than ferrous iron and is not capable of combining witb. either oxygen or carbon dioxide. Blood appears greenish brown to black in color. Increased levels result in hypoxia (Fischbach, 1992) . Common chemicals known to mediate the oxi dation of hemoglobin to methemoglobin include aniline dyes, nitrates, nitrites, and chlorates. Methemoglobin emia is particularly important for infants in that fetal hemoglobin is more easily oxidized to methemoglobin than adult hemoglobin by, for example, drinking water containing high amounts of nitrites.
Heinz bodies. Heinz bodies are inclusions observed microscopically in RBCs that represent denatured and precipitated hemoglobin and may be associated with methemoglobinemia. These can result from exposure to oxidizing chemicals and will lead to premature RBC destruction in the spleen (McKenzie et al., 1988) . He mosiderosis may be observed in various organs, partic ularly in the liver and the spleen.
2,3-Diphosphoglycerate (2,3-DPG).
Synthesized and degraded by the RBC, 2,3-DPG regulates the affinity of hemoglobin for oxygen. The oxygen affinity ofhemoglo bin is inversely proportional to the concentration of 2,3-DPG. 2,3-DPG binds reversibly to hemoglobin, sta bilizing the deoxy form (Smith, 1996) . Increased levels are associated with hypoxia (from cardiac disease, ane mia, and lung disease), uremia, and thyrotoxicosis. (Fischbach, 1992) .
Erythrocyte sedimentation rate (ESR
Myoglobin. Myoglobin is the oxygen-binding pro tein for striated muscle. An increase in myoglobin con centration in the blood may indicate muscle damage.
Reticulocytosis. Reticulocytes are immature RBCs normally present in about 1% of circulating RBCs. They usually spend 2 or 3 days in the bone marrow before being released into the circulation, where they spend an additional 1 to 2 days before becoming ma ture erythrocytes (McKenzie et al., 1988) . An increase in the circulating reticulocytes (reticulocytosis) indi cates an accelerated replacement of RBCs by the bone marrow and is a normal response to some types of anemic conditions (e.g., blood loss, hypoxia). Reticulo cytosis can, therefore, be indicative of normal bone marrow activity and erythropoiesis. Conversely, de creased reticulocyte counts in the presence of anemia can indicate bone marrow failure (Fischbach, 1992) . Reticulocytes are normally increased in pregnant women and in infants. Reticulocyte counts should be viewed in relation to the total number of erythrocytes in order to provide meaningful information.
Porphyrias. Porphyrias are a group of disorders that result from the disturbance in the heme biosyn thetic pathway, resulting in accumulation of porphy rins in tissues and excretion of large amounts in the urine and/or feces. Heme synthesis occurs primarily in the bone marrow and liver leading to the formation of hemoglobin and microsomal P450 enzymes, respec tively. Porphyrin disorders can, therefore, be separated into erythropoietic and hepatic, depending upon the site of biochemical and pathologic lesion (Fischbach, 1992; McKenzie, 1988) . The basis for erythropoietic porphyrias is an alteration of one or more enzymes in the heme synthesis pathway.
MINIMAL RISK LEVELS
Seventeen minimal risk levels based upon hemato logical effects have been derived for 12 substances (see Table 1 ). The following are some examples.
Acetone. An intermediate-duration oral MRL of 2 mg/kg/day was derived for acetone based upon a 13 week study in rats (Dietz et al., 1991; NTP, 1991) . The MRL was derived from a NOAEL of 200 mg/kg/day; a LOAEL of 400 mg/kg/day produced evidence of macro cytic anemia in the male rat (ATSDR, 1994) . The evi dence consisted of a decrease in hemoglobin concentra tion, RBCs, reticulocyte counts, and platelets and an increase in MCV and MCH. Hemosiderin deposits in the spleen were also observed.
Propylene glycol dinitrate (PGDN)
. PGDN is the major component of Otto Fuel II, a torpedo propellent used by the U.S. Navy. A chronic and an intermediate duration inhalation MRL of 0.00004 ppm was derived for PGDN based upon a study conducted in beagle dogs (ATSDR, 1995b) . At a dose level of 0.2 ppm, hemato logical effects included decreased hematocrits, RBCs, hemoglobins, and reticulocytes and an increase in met hemoglobin. Effects were first observed 4 weeks into the study period and persisted through to the end of the 14-month study period (Air Force, 1985) . PGDN elicits hematological effects typical of those observed following exposure to nitrate/nitrite compounds.
Diisopropylmethylphosphonate (DIMP). ATSDR de rived an intermediate-duration MRL of 0.8 mg/kg/day based upon a NOAEL of 75 mg/kg/day in beagle dogs (ATSDR, 1996) . In this 3-month feeding study, no clear dose-related adverse hematological effects were ob served at the highest dose tested (Hart, 1980) . How ever, Heinz body formation, reticulocytosis, and de creased RBC and hematocrit have been observed in mink at higher doses (2::345 mg/kg/day) (Bucchi et al., 1992 (Bucchi et al., , 1994 (Bucchi et al., , 1997 . These changes suggest that DIMP can cause oxidative damage to the hemoglobin, thus reducing survival time of the RBCs, which in turn induces hematopoiesis.
1,3-Dinitrobenzene. Splenic-hemosiderosis was ob served in rats exposed to 0.75 mg/kg/day of 1,3-dinitro benzene for 12 weeks (Linder et al., 1986 ). An interme diate-duration MRL of 0.0005 mg/kg/day was derived based upon this study (ATSDR, 1995c) . The hemato logic end points for this MRL are supported by other studies reporting increased erythropoietic activity, decreased hemoglobin, cyanosis, and hemosiderosis (Blackburn et al., 1988; Cody et al., 1981; Reader et al., 1991) . These effects are consistent with hemolytic ane mia following exposure to nitroso compounds.
2,4-and 2,6-Dinitrotoluene (DNT).
As with PGDN and 1,3-dinitrobenzene, the constellation of effects ob served for 2,4-and 2,6-dinitrotoluene are common to nitroaromatic compounds as well as most organic and inorganic nitrates. For DNT, these include decreased RBCs, methemoglobinemia, Heinz body formation, he mosiderosis, and reticulocytosis (ATSDR, 1997). A chronic-duration MRL of 0.002 mg/kg/day was derived for 2,4-DNT based upon a 24-month dog study (Ellis et al., 1979 (Ellis et al., , 1985 . Beagle dogs dosed once per day at 1.5 mg/kg/day developed methemoglobinemia and Heinz bodies. The MRL was based on the NOAEL of 0.2 mg/kg/day. An oral intermediate-duration MRL for 2,6 DNT was derived from another dog study by Lee et al. (1976) . Animals administered 4 mg/kg/day of 2,6-DNT were found to have extramedullary erythropoiesis and lymphoid depletion of the spleen.
CONCLUSION
Proper classification of health end points is a crucial element in the MRL development process. Oftentimes, the lines between NOAEL, LOAEL, minimal LOAEL, and serious LOAEL are not clearly defined. For hema tological effects, the degree of response is also often very important. For example, normal levels of methe moglobin in humans vary (Fischbach, 1992) . Doses causing methemoglobinemia may be considered mini mal LOAELs if the response levels measured are within a normal range, and the database for the chem ical in question supports this mechanism of toxicity. Doses causing higher levels of methemoglobin may, on the other hand, be considered serious if clinical signs of frank toxicity are observed.
Scientific judgement, coupled with the most current understanding of the chemical-specific mechanisms of action, must be used in cases such as these. Clearly then, it is important to understand not only the end point under consideration, but also the ramifications of these end points to overall human health.
